

- 
- An innovative decision-support system for improved care pathways for patients with neurodegenerative diseases and comorbidities

IHI call 1 – topic 1

# Before we start...

- We are recording this webinar and it will be published on the IHI website.
- We will also publish the presentation slides and participant list on the webinar web page.
- All information regarding future IHI call topics is indicative and subject to change until official Call launch.



# Today's webinar

- **Will cover:**

- Introduction to IHI programme
- IHI Call 1 Topic 1:
  - Challenge, need for public-private collaborative research
  - Scope, outcomes & impacts, budget
- Proposal submission, evaluation & preparation tips

- **Will not cover** rules and procedures

- The webinar on **rules and procedures** is at:  
[www.youtube.com/watch?v=qriw3AbEP-M](http://www.youtube.com/watch?v=qriw3AbEP-M)

- **Preparing proposal budgets** webinar:  
Monday 27 June | 14:30-16:00  
Register at: <https://europa.eu/!PfGJf7>



# Innovative Health Initiative

EU's new **partnership in health** between:

- the **European Union** represented by the European Commission
- &
- **Healthcare industry associations:**
  - **COCIR** (medical imaging, radiotherapy, health ICT and electromedical industries)
  - **EFPIA**, including **Vaccines Europe** (pharmaceutical and vaccine industries)
  - **EuropaBio** (biotechnology industry)
  - **MedTech Europe** (medical technology industry)

# IHI's general objectives

- Turn health research and innovation into **real benefits for patients and society**
- Deliver safe, effective health innovations that **cover the entire spectrum of care** – from prevention to diagnosis and treatment – particularly in areas where there is an unmet public health need
- Make Europe's health industries globally **competitive**.



# Strategic Research & Innovation Agenda

## Focus

- **Cross-sectoral approaches** to facilitate creation of new products and services to **prevent, intercept, diagnose, treat and manage diseases** and foster recovery more efficiently.


## Goal

- Lay foundations for development of **safer and more effective health care products or solutions** that respond to **unmet public health needs** and that can be implemented into healthcare systems.

Research supported by IHI should remain at precompetitive level



# How does IHI work? single-stage procedure



- 
- An innovative decision-support system for improved care pathways for patients with neurodegenerative diseases and comorbidities

# The challenge

- Neurodegenerative disorders represent a high societal burden impacting patients, their families, and the public health care systems.
- Patients with a neurodegenerative disorder frequently display at least one comorbidity, which together with the observed polypharmacy creates a highly complex system that needs better understanding to optimise current care pathways.



*Image by adike via Shutterstock*

# Need for public-private, cross-sector collaboration

A trusted collaborative cross-sectorial and multidisciplinary public-private partnership including:

- The end-users (importantly patients and their families/carers) for useful and usable outputs and longer-term impact.
- Different healthcare industrial sectors for delivery of meaningful converging technology-based innovations to improve healthcare.
- Further relevant interdisciplinary academic competences, including from the social sciences, and resources like data registries and cohorts to ensure all outcomes are achieved

# Scope of the topic

## What

To **develop a decision-support system** to enhance medical decisions with targeted clinical knowledge, patient information, and other health information

Address a patient population with a **neurodegenerative disease** with evidence of the importance of comorbidities.

- The choice of the **comorbidity** should consider the burden for patients, carers and families, and the availability of medical technology-generated data. Cancer is out of scope.

## Why

To achieve a **more holistic** (breaking silos across medical specialties) **approach** to managing and treating patients with a neurodegenerative disease and a comorbid condition

- addressing the **needs of today** and **creating preparedness** for a future paradigm-shift in treatment.
- to **improve care and treatment outcomes**, considering implementation into routine care and sustainability, which if not tackled could be barriers to developing and distributing/delivering innovations

# Expected outcomes

- A **digital platform** to guide patients and healthcare professionals, easy adaptable for re-use in other health areas
- A **sustainable framework for collaboration** across specialties and stakeholders to foster social innovation
- **Standards and guidelines** for data collection and operation of the digital platform enabling medical technology innovation
- Enhanced, more reliable **tools and methods for (near) real time feedback on health interventions**, to support joint patient/doctor decision making
- Enhanced **clinical interpretation of complex data** influencing variations in patient status and required care, for the benefit of patients and healthcare providers

# Expected impact

- **Enhanced cross-sectoral collaboration** between healthcare industries, academia, and all relevant actors of the healthcare ecosystem for exchange of resources beyond data.
- Earlier and more precise **diagnosis**, more clinically effective **interventions**, better patient **adherence**, and **reduced hospitalisation** (reduction in re-admission/period of hospitalisation).
- A **patient stratification** able to better predict clinical outcomes to support more patient-adapted interventions / (novel) therapeutics.
- Better **patient clinical outcomes** and improved patient **experience** for patients with neurodegenerative diseases.
- More **cost-effective** and better **prepared care pathway management** for patients with neurodegenerative diseases.
- **Contribute** to the 'European Health Data Space' objectives.

# Dissemination, exploitation and communication

- Crucial to ensure **take up of project results** after the funding ends.
  - **Long term impact**
- In your proposal, you must:
  - Describe the activities that are planned
  - Describe the target group(s) addressed
  - Reserve sufficient resources for these activities

# Budget & Duration

## **BUDGET**

- Total of EUR 15 million public funding available for this topic
- IHI estimates that an IHI financial contribution of around EUR 5 000 000 to 7 000 000 would allow a proposal to address the topic outcomes appropriately.
- At least 45% of the total budget of each project must be covered by contributions provided by IHI Private members & Contributing partners

## **DURATION**

- Applicants should propose a project duration such that it matches project activities and expected outcomes and impacts

# Simplified example budget

Participant type	Total costs	Requested IHI funding	In-kind contributions (IKOP, IKAA, FCs)
<b>'Public' partners</b> (Universities, hospitals, SMEs, patient orgs, regulators.....)	5 million	5 million	0
<b>Private members &amp; Contributing partners</b>	5 million	0	5 million
<b>Total</b>	<b>10 million</b>	<b>5 million (50%)</b>	<b>5 million (50%)</b>



# Proposal Submission & Evaluation

# Proposal Template - Parts A, B & Annexes

- **Part A** of the proposal is **administrative data** that is entered in webforms through the Funding & Tenders Portal.
- **Part B** of the proposal is the **narrative part** that includes three sections:
  - Excellence
  - Impact
  - Quality and efficiency of the implementation
- **Read instructions** in proposal template **very carefully**
- **Annexes:**
  - Participant type
  - Budget details
  - Clinical studies template

# Evaluation Criteria (1/2)

## ● Excellence

- Clarity and pertinence of the project's objectives, and the extent to which the proposed work is ambitious, and goes beyond the state of the art.
- Soundness of the proposed methodology, including the underlying concepts, models, assumptions, interdisciplinary approaches, appropriate consideration of the gender dimension in research and innovation content, and the quality of open science practices, including sharing and management of research outputs and engagement of citizens, civil society and end users where appropriate.

## ● Impact

- Credibility of the pathways to achieve the expected outcomes and impacts specified in the work programme, and the likely scale and significance of the contributions due to the project.
- Suitability and quality of the measures to maximise expected outcomes and impacts, as set out in the dissemination and exploitation plan, including communication activities.

# Evaluation Criteria (2/2)

- **Quality and efficiency of the implementation**
  - Quality and effectiveness of the work plan, assessment of risks, and appropriateness of the effort assigned to work packages, and the resources overall
  - Capacity and role of each participant, and extent to which the consortium as a whole brings together the necessary expertise.



- Tips for applicants

# Tips for applicants

- Read all the call-relevant material, especially the **topic text**
  - [www.ihl.europa.eu/apply-funding/open-calls](http://www.ihl.europa.eu/apply-funding/open-calls)
  - [www.ihl.europa.eu/apply-funding/future-opportunities](http://www.ihl.europa.eu/apply-funding/future-opportunities)
- Form your consortium **early**
  - Always think “public-private partnership“
  - Include partners bringing **in-kind contributions**
- Ensure that **all information requested in the call text and proposal template** is provided to allow the evaluation experts to easily assess your proposal against the evaluation criteria
- Consider & plan for the potential **regulatory impact** of results



# Finding project partners

You'll need to build or join a consortium!

- Network with **your contacts, webinar & brokerage event participants:**

- [ihi-calls-2022.b2match.io/components/20715](https://ihi-calls-2022.b2match.io/components/20715)

- Use EU Funding & Tenders portal **partner search tool:**

- <https://europa.eu/!QU87Nx>

- Get in touch with your **IHI national contact point:**

- <https://europa.eu/!D7jyMy>

- Network on social media:

- [www.twitter.com/IHIEurope](https://www.twitter.com/IHIEurope)

- [be.linkedin.com/company/innovative-health-initiative](https://be.linkedin.com/company/innovative-health-initiative)





- Additional Slides

# Simplified example budget

Participant type	Total costs	Requested IHI funding	In-kind contributions (IKOP, IKAA, FCs)
<b>'Public' partners</b> (Universities, hospitals, SMEs, patient orgs, regulators.....)	15 million	15 million	0
<b>Private member 1</b>	15 million	0	15 million
<b>Private member 2</b> 'hybrid'	10 million	5 million	5 million
<b>Total</b>	<b>40 million</b>	<b>20 million</b> (50%)	<b>20 million</b> (50%)



Thank you for your attention

[ihi.europa.eu](http://ihi.europa.eu)

